These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10412754)

  • 1. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group.
    Muso E; Mune M; Fujii Y; Imai E; Ueda N; Hatta K; Imada A; Miki S; Kuwahara T; Takamitsu Y; Takemura T; Tsubakihara Y
    Kidney Int Suppl; 1999 Jul; 71():S122-5. PubMed ID: 10412754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome.
    Sakurai M; Muso E; Matushima H; Ono T; Sasayama S
    Kidney Int Suppl; 1999 Jul; 71():S210-2. PubMed ID: 10412778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.
    Hattori M; Chikamoto H; Akioka Y; Nakakura H; Ogino D; Matsunaga A; Fukazawa A; Miyakawa S; Khono M; Kawaguchi H; Ito K
    Am J Kidney Dis; 2003 Dec; 42(6):1121-30. PubMed ID: 14655182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis?
    Muso E; Yashiro M; Matsushima M; Yoshida H; Sawanishi K; Sasayama S
    Nephrol Dial Transplant; 1994; 9(3):257-64. PubMed ID: 8052431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS).
    Muso E; Mune M; Yorioka N; Nishizawa Y; Hirano T; Hattori M; Sugiyama S; Watanabe T; Kimura K; Yokoyama H; Sato H; Saito T
    Clin Nephrol; 2007 Jun; 67(6):341-4. PubMed ID: 17598368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy.
    Muso E; Mune M; Fujii Y; Imai E; Ueda N; Hatta K; Imada A; Takemura T; Miki S; Kuwahara T; Takamitsu Y; Tsubakihara Y;
    Nephron; 2001 Dec; 89(4):408-15. PubMed ID: 11721158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.
    Muso E; Mune M; Hirano T; Hattori M; Kimura K; Watanabe T; Yokoyama H; Sato H; Uchida S; Wada T; Shoji T; Yuzawa Y; Takemura T; Sugiyama S; Nishizawa Y; Ogahara S; Yorioka N; Sakai S; Ogura Y; Yukawa S; Iino Y; Imai E; Matsuo S; Saito T
    Clin Exp Nephrol; 2015 Jun; 19(3):379-86. PubMed ID: 24934117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion.
    Stenvinkel P; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 2000 Oct; 30(10):866-70. PubMed ID: 11029600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Clin Nephrol; 2006 Jan; 65(1):1-6. PubMed ID: 16429835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment].
    Okada T; Takahashi H; Ogura M; Nakao T; Shimizu T
    Nihon Jinzo Gakkai Shi; 1996 Jan; 38(1):46-51. PubMed ID: 8855137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Excellent antiproteinuric effect by LDL apheresis in a case with severe renal dysfunction due to focal segmental glomerulosclerosis].
    Iwahori T; Yoshida M; Sugiura M; Ioya N; Kawaguchi M
    Nihon Jinzo Gakkai Shi; 1996 Feb; 38(2):91-7. PubMed ID: 8717311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on LDL apheresis for nephrotic syndrome.
    Raina R; Krishnappa V
    Pediatr Nephrol; 2019 Oct; 34(10):1655-1669. PubMed ID: 30218191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis.
    Kawasaki Y; Suzuki S; Matsumoto A; Takano K; Suyama K; Hashimoto K; Suzuki J; Suzuki H; Hosoya M
    Pediatr Nephrol; 2007 Jun; 22(6):889-92. PubMed ID: 17277952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis.
    Oto J; Suga K; Matsuura S; Kondo S; Ohnishi Y; Inui D; Imanaka H; Kagami S; Nishimura M
    J Anesth; 2009; 23(2):284-7. PubMed ID: 19444573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy.
    Yokoyama K; Sakai S; Sigematsu T; Takemoto F; Hara S; Yamada A; Kawaguchi Y; Hosoya T
    Clin Nephrol; 1998 Jul; 50(1):1-7. PubMed ID: 9710340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low density lipoprotein apheresis ameliorates interferon-γ production in patients with nephrotic syndrome.
    Miyata H; Uno K; Ono T; Yashiro M; Fukatsu A; Kita T; Kimura T; Muso E
    Ther Apher Dial; 2012 Apr; 16(2):189-94. PubMed ID: 22458400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
    Tojo K; Sakai S; Miyahara T
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1153-60. PubMed ID: 3216557
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.
    Hattori M; Ito K; Kawaguchi H; Tanaka T; Kubota R; Khono M
    Pediatr Nephrol; 1993 Apr; 7(2):196-8. PubMed ID: 8476719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
    Tojo K; Sakai S; Miyahara T
    Prog Clin Biol Res; 1990; 337():193-4. PubMed ID: 2191313
    [No Abstract]   [Full Text] [Related]  

  • 20. A case report of nephrotic syndrome due to collapsing focal segmental glomerulosclerosis treated with low-density lipoprotein apheresis.
    Miyazono M; Tomiyoshi Y; Kishi T; Ikeda Y; Sakemi T; Sanai T; Node K
    Ther Apher Dial; 2008 Aug; 12(4):333-6. PubMed ID: 18789122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.